Caribou Biosciences Inc
Company Profile
Business description
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
Contact
2929 7th Street
Suite 105
BerkeleyCA94710
USAT: +1 510 982-6030
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
147
Stocks News & Analysis
stocks
Chart of the Week: Inflation fears dampen sentiment on retailers
stocks
Here’s 3 Top Rated ASX shares for 2026
stocks
Undervalued Aussie e-commerce winner
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,046.50 | 7.00 | 0.08% |
| CAC 40 | 8,243.47 | 6.04 | 0.07% |
| DAX 40 | 25,080.10 | 42.16 | -0.17% |
| Dow JONES (US) | 49,272.53 | 276.45 | 0.56% |
| FTSE 100 | 10,021.34 | 26.87 | -0.27% |
| HKSE | 26,149.31 | 561.14 | -2.10% |
| NASDAQ | 23,434.53 | 112.65 | -0.48% |
| Nikkei 225 | 51,117.26 | 1,400.82 | -2.67% |
| NZX 50 Index | 13,716.86 | 1.84 | 0.01% |
| S&P 500 | 6,915.97 | 4.96 | -0.07% |
| S&P/ASX 200 | 8,720.80 | 2.70 | -0.03% |
| SSE Composite Index | 4,082.98 | 2.79 | -0.07% |